{"topic_id":"ade_recombinant_human_insulin_adverse_events","category":"ade","context":"---\ntopic_id: ade_recombinant_human_insulin_adverse_events\ncategory: ade\ntitle: \"FDA ADE reports for Recombinant Human Insulin (active ingredient) — total reports, species & reaction breakdown\"\nlang: en\nsource: \"openFDA animalandveterinary/event.json (FDA CVM adverse event reports), pulled 2026-07-22\"\nsource_file: pdf-raw/ade/ade_active_ingredients_2026-07-22_b14.json\ndate_parsed: 2026-07-22\ntokens_estimated: 360\nverification:\n  method: substring_match\n  claims: 30\n  passed: 30\n  date: 2026-07-22\n---\n\n# Recombinant Human Insulin — FDA Animal & Veterinary Adverse Event (ADE) Reports\n\nSource: openFDA `animalandveterinary/event.json`, the FDA Center for Veterinary Medicine (CVM) adverse event report database. Data pulled 2026-07-22. Counts are report-level: one report may list multiple reactions and multiple animals, so figures are not additive and do not imply causation. Recombinant Human Insulin is a active ingredient.\n\n## Total reports\nRecombinant Human Insulin: 1670\n\n## Reports by species (top entries)\n- Dog 1021\n- Cat 471\n- Human 7\n-  6\n\n## Top reported reactions (VEDDRA terms, top entries)\n- Vomiting 223\n- Lack of efficacy - NOS 182\n- Lethargy (see also Central nervous system depression in 'Neurological') 176\n- INEFFECTIVE, GLYCEMIC CONTROL 159\n- Hypoglycaemia 158\n- Decreased appetite 98\n- Uncoded sign 84\n- Cataract 69\n- Suspension, Abnormal 69\n- Diarrhoea 68\n\nSource JSON: `pdf-raw/ade/ade_active_ingredients_2026-07-22_b14.json` (openFDA animalandveterinary/event.json, pulled 2026-07-22).\n","sources":[],"tokens_estimated":253,"generated_at":null,"tip":"Use /api/v1/topics to discover more topics. /api/v1/nutrient for precise single-point queries. /api/v1/cross_compare for 2-3 standard comparisons."}